A randomized, parallel group, open-label, multicenter study to investigate the efficacy and safety of oral BAY 85-3934 and active comparator (darbepoetin alfa) in the maintenance treatment of anaemia in pre-dialysis subjects with chronic kidney disease on darbepoetin treatment in Europe and Asia Pacific
Latest Information Update: 12 Dec 2021
At a glance
- Drugs Molidustat (Primary) ; Darbepoetin alfa; Darbepoetin alfa
- Indications Anaemia
- Focus Therapeutic Use
- Acronyms DIALOGUE 2
- Sponsors Bayer; Bayer HealthCare
- 10 Jan 2020 Results (N=42), assessing drug-drug interaction of Molidustat with iron and calcium supplements in patients with anemia as a result of chronic kidney disease, published in the European Journal of Clinical Pharmacology
- 11 Dec 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 09 Jul 2015 Planned End Date changed from 1 Mar 2016 to 1 Dec 2016 as reported by ClinicalTrials.gov record.